Blog
ESMO: With massive tumor progression edge, AstraZeneca-Daiichi's Enhertu shows Roche's Kadcyla who's the better breast cancer drug
ESMO: With massive
tumor progression edge, AstraZeneca-Daiichi's Enhertu shows Roche's
Kadcyla who's the better breast cancer drugContinue reading at the link below:https://www.fiercepharma.com/pharma/massive-tumor-...
…
Sep 24th 2021
Study confirms GSK-Vir mAb reduces COVID hospitalization
Study confirms GSK-Vir mAb reduces COVID hospitalizationRead more at the link below;https://www.pharmamanufacturing.com/industrynews/2...
…
Jun 21st 2021
Two shots of Pfizer, AstraZeneca COVID-19 vaccines effective against Delta variant: study
Two shots of Pfizer, AstraZeneca COVID-19 vaccines effective against Delta variant: studyhttps://www.fiercepharma.com/pharma/two-shots-pfiz...
…
Jun 15th 2021
Novavax COVID-19 vaccine hits 90% efficacy in pivotal U.S. trial
Novavax COVID-19 vaccine hits 90% efficacy in pivotal U.S. trialRead more at the link below;https://www.fiercebiotech.com/biotech/novavax-covi...
Jun 14th 2021
Johnson & Johnson snares FDA nod for first exon 20-targeted drug in EGFR lung cancer
Johnson & Johnson snares FDA nod for first exon 20-targeted drug in EGFR lung cancerMore details at the link below.https://www.fiercepharma.com/pharma/johnson-johnso...This news article is shared for information purposes. Published by Fiercepharma.
…
May 28th 2021